DHVI Postdoc Ashley Nelson Awarded the Duke Clinical Translational Science Award (CTSA) Postdoctoral TL1
Congratulations to Dr. Ashley Nelson for being awarded the Duke Clinical Translational Science Award (CTSA) Postdoctoral TL1. Dr. Nelson is one of two people at Duke selected for this award. Her proposal was titled: Determinants of neutralizing antibody breadth in HIV-infected children.
A vaccine that can protect prior to sexual debut is critical for elimination of the estimated 590,000 new HIV infections that occur yearly in adolescents and young adults (ages 15-24 years). A vaccine designed to protect from HIV in adolescence would ideally be implemented during early childhood, and will likely require the elicitation of broadly neutralizing antibodies (bnAbs). This study will advance our current understanding on how neutralization breadth develops in the setting of early life immune system maturation, and inform pediatric bnAb lineage-based HIV vaccine strategies designed to protect prior to sexual debut.
Dr. Nelson will be conducting this work under the mentorship of DHVI Investigators Drs. Sallie Permar and Genevieve Fouda.